新型三嗪类化合物作为治疗多种疾病的NLRP3抑制剂
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
Abstract
Provided herein are novel triazines as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.
摘要
本文提供了作为NLRP3抑制剂的新型三嗪、药物组合物、此类化合物在治疗多种疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.新型三嗪类化合物作为治疗多种疾病的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
2
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
3
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.作为用于治疗阿尔茨海默病和帕金森病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
4
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.新型三嗪衍生物作为治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
5
Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.哒嗪类化合物作为用于治疗帕金森病或额颞叶痴呆的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 7;15(12):2083-2084. doi: 10.1021/acsmedchemlett.4c00523. eCollection 2024 Dec 12.
6
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的单酰甘油脂肪酶抑制剂的新型杂环化合物。
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
7
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.新型咪唑并吡啶和咪唑并哒嗪衍生物作为治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂
ACS Med Chem Lett. 2024 Jul 3;15(8):1180-1181. doi: 10.1021/acsmedchemlett.4c00286. eCollection 2024 Aug 8.
8
Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂的吡唑并吡啶和三唑并吡啶衍生物
ACS Med Chem Lett. 2024 Oct 14;15(11):1806-1807. doi: 10.1021/acsmedchemlett.4c00485. eCollection 2024 Nov 14.
9
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂的新型三唑并吡啶衍生物
ACS Med Chem Lett. 2024 Aug 21;15(9):1435-1436. doi: 10.1021/acsmedchemlett.4c00408. eCollection 2024 Sep 12.
10
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
本文引用的文献
1
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.作为用于治疗阿尔茨海默病和帕金森病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
2
Role of NLRP3 in Parkinson's disease: Specific activation especially in dopaminergic neurons.NLRP3在帕金森病中的作用：特异性激活，尤其是在多巴胺能神经元中。
Heliyon. 2024 Mar 28;10(7):e28838. doi: 10.1016/j.heliyon.2024.e28838. eCollection 2024 Apr 15.
3
NLRP3 inflammasome signalling in Alzheimer's disease.NLRP3 炎性小体在阿尔茨海默病中的作用机制。
Neuropharmacology. 2024 Jul 1;252:109941. doi: 10.1016/j.neuropharm.2024.109941. Epub 2024 Mar 31.
4
Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action.通过 AMP 激活的蛋白激酶通路靶向阿尔茨海默病的植物化学物质、作用及作用机制。
Biomed Pharmacother. 2024 Apr;173:116373. doi: 10.1016/j.biopha.2024.116373. Epub 2024 Mar 4.
5
Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue.糖原合酶激酶 3β（GSK-3β）抑制剂在帕金森病中的治疗潜力：探索被忽视的途径。
Mol Neurobiol. 2024 Sep;61(9):7092-7108. doi: 10.1007/s12035-024-04003-z. Epub 2024 Feb 17.
6
Molecular crosstalk between circadian clock and NLRP3 inflammasome signaling in Parkinson's disease.帕金森病中昼夜节律与NLRP3炎性小体信号通路之间的分子串扰
Heliyon. 2024 Jan 14;10(2):e24752. doi: 10.1016/j.heliyon.2024.e24752. eCollection 2024 Jan 30.
Zotero 插件